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Abstract 
Routinely collected data about health in medical records, 
registries and hospital activity statistics is now routinely collected in an 
electronic form. The extent to which such sources of data are now 
being routinely accessed to deliver efficient clinical trials, is unclear. 
The aim of this study was to ascertain current practice amongst a 
United Kingdom (UK) cohort of recently funded and ongoing 
randomised controlled trials (RCTs) in relation to sources and use of 
routinely collected outcome data. 
Recently funded and ongoing RCTs were identified for inclusion by 
searching the National Institute for Health Research journals library. 
Trials that have a protocol available were assessed for inclusion and 
those that use or plan to use routinely collected health data (RCHD) 
for at least one outcome were included. RCHD sources and outcome 
information were extracted. 
Of 216 RCTs, 102 (47%) planned to use RCHD. A RCHD source was the 
sole source of outcome data for at least one outcome in 46 (45%) of 
those 102 trials. The most frequent sources are Hospital Episode 
Statistics (HES) and Office for National Statistics (ONS), with the most 
common outcome data to be extracted being on mortality, hospital 
admission, and health service resource use. 
Our study has found that around half of publicly funded trials in a UK 
cohort (NIHR HTA funded trials that had a protocol available) plan to 
collect outcome data from routinely collected data sources. This is 
much higher than the figure of 8% found in a cohort of 189 RCTs 
published since 2000, the majority of which were carried out in North 
America (McCord et al., 2019).
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Introduction
Routinely collected data about health in medical records, reg-
istries and hospital activity statistics is now routinely collected 
in an electronic form. Progress in achieving connectivity, data 
linkage and security now offers the possibility of better use 
of this data for research purposes. For example, recent evi-
dence shows the utility of long-term follow-up of trial patients 
by linkage to routinely collected health data (RCHD) sources 
(Fitzpatrick et al., 2018). Innovative data-enabled study designs 
can answer pressing knowledge gaps in research evidence. How-
ever, the extent to which such sources of data are now being 
routinely employed in research to deliver efficient clinical 
trials, potentially at a wide scale, is unclear.
The aim of this study was to ascertain current practice amongst 
a United Kingdom (UK) cohort of recently funded and ongo-
ing randomised controlled trials (RCTs) in relation to sources 
and use of routinely collected outcome data. We define 
RCHD to be data collected without specific a priori research 
questions developed prior to using the data for research.
Methods
Inclusion criteria
The following inclusion criteria were used: 
1.    Ongoing RCT of any type including feasibility or pilot 
work, funded by the National Institute for Health 
Research (NIHR) Health Technology Assessment 
(HTA) programme;
2.    availability of a protocol; and
3.    use of RCHD for at least one study outcome.
Search methods
A search of the NIHR Journals Library was undertaken to find 
protocols registered as of 25/10/2019. The search fields and 
terms used to select were: 
1.    Search term: ‘Random’
2.    Research type: ‘Primary research’
3.    Programme: ‘HTA’
4.    Status: ‘Research in progress’
If the final published report was shown alongside the protocol 
this was taken to mean that the RCT was not ongoing but the 
status had not been updated to ‘Published’, and the study was 
excluded.
In the absence of a protocol, the study was excluded. For stud-
ies with multiple protocol versions, the most recently available 
version was used.
Data extraction
One person (AM) extracted the information and categorised 
each RCHD source, with a second person (PW) checking 
classifications and explanations. The information extracted was 
as follows: Lead Investigator surname, year started, ISRCTN, 
project title, study type, use of RCHD for at least one study 
outcome, availability of a protocol, any details of data quality 
assessment of RCHD source prior to use, RCHD source name, 
reasons for wanting outcome data from RCHD source, specific 
outcomes and outcome type where clear data to be used will 
come from named RCHD sources.
Results
Figure 1 shows the study flow diagram. 279 records were iden-
tified through database searching and screened for inclusion. 
22 were non-RCTs, 1 was a completed RCT, 30 were 
RCTs but no protocol was available and 10 were unclear. Of 
the remaining 216 NIHR HTA trials with a protocol available 
for further study, 102 (47%) planned to use RCHD for at least 
one outcome.
Table 1 shows the reasons for collecting trial outcome data from 
routine sources from the 102 eligible trials. The RCHD source 
was the sole source of outcome data for at least one outcome in 
46 (45%) of those 102 trials (categories 3, 4 and 6 in Table 1). 
In five of these 46 protocols there was reference to prior fea-
sibility work confirming aspects of the quality of the data 
to be sufficient for the main trial. Of the 102 trials, 14 
(categories 7a-7d in Table 1) planned to assess the feasibility 
of using the RCHD sources during the trial, although details of 
the assessment were often lacking. Raw data for Figure 1 and 
Table 1 and Table 2 are available (see Underlying data, McKay 
et al. (2020)).
Table 2 shows the RCHD sources of outcome data to be used 
in these 46 studies. The most frequent RCHD sources are 
Hospital Episode Statistics (HES) and Office for National 
Statistics (ONS), with the most common outcome data to 
be extracted being on mortality, hospital admission, and 
health service resource use (see Underlying data, Data Set 5; 
McKay et al. (2020)). The full list of RCHD sources is given in 
Extended data, Supplementary Table 1 (McKay et al., 2020).
Discussion
Our study has found that around half of publicly funded trials 
in a UK cohort (NIHR HTA funded trials that had protocol 
available) plan to collect outcome data from RCHD sources. 
This is much higher than the figure of 8% found in a cohort 
of 189 RCTs published since 2000, the majority of which 
were carried out in North America (McCord et al., 2019).
Very few trial teams described any assessments of data quality 
from RCHDs in the protocol. Work is ongoing that should 
            Amendments from Version 1
Clarifications/edits made in response to comments by Reviewer 
#1. The main changes being (i) we have now made it clear that 
the “UK cohort” is “NIHR HTA trials with a protocol” ongoing at 
the stated data extraction date; (ii) we have emphasised that the 
main result is that of 102 protocols using routinely collected data 
for an outcome, 46 were using routinely collected data as their 
sole source for at least one outcome; (iii) we have chosen to use 
‘routinely collected health data (RCHD)’ throughout rather than 
‘Electronic Health Record (EHR)’ for consistency. 
Any further responses from the reviewers can be found at the 
end of the article
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Table 1. Reasons for sourcing outcome data from RCHD sources in 102 studies. Multiple categories can apply to a single 
study.
Categories Total
(1) (1a) ‘Supplementing data collection for withdrawn patients (consent asked for at time of withdrawal)’ 7
(1b) ‘Supplementing data collection for lost-to-follow-up patients’ 8
(1c) ‘Supplementing data collection for withdrawn patients (consent NOT ASKED FOR at time of withdrawal)’ 2
(1e) ‘Continued data collection for withdrawn patients (consent asked for at time of withdrawal)’ 1
(2) (2) ‘Supplementing data collection for unobtainable/missing data’ 3
(3) (3a) ‘As the sole source of all outcome data’ 0
(3b) ‘As the sole source of all outcome data except for data related to protocol adherence and adverse event 
reporting being collected using CRFs’ 0
(4) (4) ‘As the sole source of some outcome data’ 43
(5) (5a) ‘As a source of some outcome data, alongside other sources for the same outcome data (e.g. CRF)’ 51
(5b) ‘As a source of some outcome data, but collected by CRF if unable to access data’ 3
Figure 1. PRISMA flow diagram.
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Table 2. Categories of RCHD sources of outcome data in 
46 studies where this was the sole source for at least one 
outcome.
Source Number (%)
(i) Primary care data (all regional equivalents) 8 (17%)
(ii) HES (and/or regional equivalents) 27 (59%)
(iii) ONS (and/or regional equivalents) 27 (59%)
(iv) Data collected specifically for patient group 
or healthcare intervention (to include patient 
registries, ICNARC, ambulance, etc)
26 (57%)
(v) Other 5 (11%)
Categories Total
(6) (6a) ‘Registry trial*: As the sole source of outcome data with purpose-built Module to collect remaining outcome data’ 1
(6b) ‘Registry trial*: All outcome data collected through multiple RCHD sources except for questionnaire data’ 1
(6c) ‘Registry trial*: All outcome data collected through multiple RCHD sources except for some baseline data, 
questionnaire data and other patient-reported data’ 1
(7) (7a) ‘RCHD compared to trial collected data as part of feasibility assessment criteria’ 11
(7b) ‘RCHD compared to trial collected data as a main trial secondary outcome’ 1
(7c) ‘RCHD compared to trial collected data and then collect long-term follow-up data as part of trial’ 1
(7d) ‘RCHD compared to trial collected data and then collect long-term follow-up data after trial has been 
completed’ 1
(7e) ‘Representativeness of randomised patients compared with all eligible patients using RCHD as part 
of feasibility assessment criteria’ 1
(8) (8a) ‘Participants flagged with NHS Digital/other: Check health status of patient prior to contacting in case patient has died’ 2
(8b) ‘Participants flagged with NHS Digital/other: Check health status/notification of any deaths, causes’ 12
(9) (9) ‘Set up mechanisms for long-term follow-up’ 4
(10)
(10) ‘Patients asked to provide written consent for continuation in the study once have regained capacity. 
Those who prefer not to be actively involved in the study follow-up, then asked to provide consent to using their 
routinely collected NHS data’
1
Total 155
* A registry trial is a RCT conducted using clinical observational registries as the main source of outcome data collection
determine whether such information should be reported in the 
trial publication (Kwakkenbos et al., 2018). An extension to 
the SPIRIT guidelines for trials using RCHD is soon to be 
initiated, and will determine whether this information should be 
included in the trial protocol. As a minimum, it is recommended 
that trialists provide evidence in any funding application about 
the quality of the data from the RCHD source.
Data availability
Underlying data
Figshare: Use of routinely collected data in a UK cohort of 
publicly funded randomised clinical trials. https://doi.org/ 
10.6084/m9.figshare.12185193 (McKay et al., 2020).
This project contains the following underlying data: 
•    Data_Set_1_Details_and_Figure_1_v1.0.csv. (Study identi-
fiers and raw data used for Figure 1.)
•    Data_Set_2_Table_1_v1.0.csv. (Raw data used for 
Table 1.)
•    Data_set_3_Supp_Table_1_v1.0.csv. (Raw data used for 
Supplementary Table 1.)
•    Data_set_4_Table_2_v1.0.csv. (Raw data used for 
Table 2.)
•    Data_set_5_Outcomes_using_EHR_data_v1.0.csv. (Raw 
data showing details of outcomes using data from RCHD 
sources.)
Extended data
Figshare: Use of routinely collected data in a UK cohort 
of publicly funded randomised clinical trials. https://doi.
org/10.6084/m9.figshare.12185193 (McKay et al., 2020).
This project contains the following extended data: 
•    Supplementary Table 1 - EHR sources of outcome 
data v1.0.pdf. (Supplementary Table 1.)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Merrick Zwarenstein  
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A sentence could be included to explain your rationale for selecting trials from the Health 
Technology Assessment Programme at NIHR as against some other source of publicly funded 
trials. For example your study excludes UKMRC funded trials. The implications of excluding these 
mechanism-of-action and therapeutic intervention trials could be explained in the discussion.    
  
Your flow diagram indicates that you identified articles through database searching (NIHR 
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were searched, and why?  
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Sharon Love   
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This is a review of the protocols of RCTs, currently in progress, funded by NIHR, UK. RCTs were 
selected from NIHR HTA funding stream list if they claimed to be using routinely collected data for 
at least one study outcome. The authors found 102 trial protocols matching this criteria and from 
data extraction that 46 of these were using routinely collected data solely for at least one 
outcome. The research also found that a handful referenced previous feasibility work confirming 
the quality of the EHR and also gives a useful table categorising for the 102 trials how they used 
EHR. 
 
Major Comments 
I have only one major comment and it is the reason for both the ‘partly’ options below. The sample 
was selected to be using routinely collected data for at least one study outcome. Therefore I think 
the main result should contain this information. I consider that “in a UK cohort” is not enough of a 
description of the cohort. The fact that the sample was selected based on using routine data for an 
outcome is crucial in the interpretation. 
 
The main result is that of 102 protocols using routinely collected data for an outcome, 46 were 
using routinely collected data as their sole source for at least one outcome. 46/102=45%. Around a 
half of NIHR HTA funded trials that had an uploaded protocol and used routinely collected health 
data for at least one study outcome, used solely routinely collected data for at least one trial 
outcome. 
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I think this is an important result. 
 
Minor comments
Abstract – last part of the last sentence has a word missing “The majority of which were 
carried out in North America”. 
 
1. 
If you have space in the text, it would be useful to add the information that 30 were omitted 
due to not having a protocol. 
 
2. 
The flow chart shows you selected the papers by selecting RCT, those that had a protocol 
and then those using routinely collected data for at least one outcome. I would be tempted 
to list the inclusion criteria in the paper in the same order. 
 
3. 
The second inclusion criteria is “use of routinely collected health data”. Elsewhere you use 
the term EHR. I would be tempted to be consistent. 
 
4. 
Table 1: category 10 description appears incomplete. 
 
5. 
Table 1: could you add a footnote of the definition of a registry trial?6. 
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